Login to Your Account

Transcept's Roller Coaster Year Ends with Intermezzo Approval

By Jennifer Boggs
Managing Editor

Monday, November 28, 2011
Back in July, it looked like Transcept Pharmaceutical Inc.'s insomnia drug Intermezzo (zolpidem tartrate) was down for the count. The company, aiming to provide the first treatment specifically for middle-of-the-night waking, had just gotten a surprise second complete response letter (CRL), despite conducting the FDA-requested next-day highway driving study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription